相关实验视频
Updated: Jul 19, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
用Janus激酶抑制剂治疗的患者的心血管风险管理
Jill T Shah1, Keya T Shah2, Alisa N Femia1,3
1New York University Grossman School of Medicine, New York, NY.
Journal of cardiovascular pharmacology
|August 11, 2023
概括
简氏激酶抑制剂 (JAKi) 治疗免疫介导的炎症性疾病,但携带血液凝块和心血管事件的风险. 心脏病专家是管理JAKi治疗患者这些风险的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏酶信号转换器和转录激活器 (JAK-STAT) 途径在免疫介导炎症性疾病 (IMID) 中至关重要.
- 简氏激酶抑制剂 (JAKi) 是各种IMID的有效治疗方法.
- 随着JAKi的使用,特别是口服托法西替尼,在ORAL监测试验之后,有关静脉血栓栓塞 (VTE) 和心血管 (CV) 事件的担忧出现了.
研究的目的:
- 审查使用JAKi治疗的IMID患者中CV风险的当前文献.
- 在接受JAKi治疗的患者中识别VTE和CV事件的潜在风险因素.
- 提出一种系统的方法来评估和管理考虑或服用JAKi的患者的CV风险.
主要方法:
- 关于JAKi,IMID,VTE和CV事件的综合文献综述研究.
- 分析ORAL监控试验数据和随后的监管警告.
- 识别和综合与JAKi和心血管结果相关的风险因素.
主要成果:
- 在ORAL监测试验中,在高风险的类风湿性关节炎患者中,托法西替尼增加了VTE和CV事件风险.
- 监管机构将关于VTE和CV风险的警告扩展到其他JAKi,包括专题配方,引起争议.
- 在接受JAKi治疗的患者中,已经确定了VTE和CV事件的几种潜在风险因素.
结论:
- 心脏病学家在JAKi治疗患者的风险分层和缓解方面发挥着至关重要的作用.
- 建议采用综合的多模式方法来评估JAKi考虑的患者的CV风险.
- 用JAK抑制剂治疗IMID的患者,特别是那些具有先前存在的风险因素或长期治疗的患者,管理心血管风险至关重要.
相关概念视频
Rheumatic Heart Disease III: Medical Management
13
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
13
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
204
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
204
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Rheumatic Heart Disease IV: Nursing Management
18
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
18
Myocarditis III: Medical Management
9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K

